blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3794024

EP3794024 - ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.03.2024
Database last updated on 13.11.2024
FormerThe patent has been granted
Status updated on  07.04.2023
FormerGrant of patent is intended
Status updated on  02.01.2023
FormerExamination is in progress
Status updated on  14.10.2021
FormerRequest for examination was made
Status updated on  19.02.2021
FormerThe international publication has been made
Status updated on  22.11.2019
Formerunknown
Status updated on  18.06.2019
Most recent event   Tooltip17.05.2024Lapse of the patent in a contracting state
New state(s): SI		published on 19.06.2024  [2024/25]
Applicant(s)For all designated states
WEREWOLF THERAPEUTICS, INC.
200 Talcott Avenue
Watertown, MA 02472 / US
[2023/31]
Former [2023/19]For all designated states
WEREWOLF THERAPEUTICS, INC.
1030 Massachusetts Avenue
Cambridge, MA 02138 / US
Former [2021/12]For all designated states
WEREWOLF THERAPEUTICS, INC.
1030 Massachusetts Avenue
Cambridge, MA 02138 / US
Inventor(s)01 / WINSTON, William
c/o Werewolf Therapeutics, Inc.
1030 Massachusetts Avenue
Cambridge, Massachusetts 02138 / US
02 / HICKLIN, Daniel
c/o Werewolf Therapeutics, Inc.
1030 Massachusetts Avenue
Cambridge, Massachusetts 02138 / US
03 / BHASKAR, Vinay
c/o Werewolf Therapeutics, Inc.
1030 Massachusetts Avenue
Cambridge, Massachusetts 02138 / US
04 / EVNIN, Luke
c/o Werewolf Therapeutics, Inc.
1030 Massachusetts Avenue
Cambridge, Massachusetts 02138 / US
05 / BAEUERLE, Patrick
c/o Werewolf Therapeutics, Inc.
1030 Massachusetts Avenue
Cambridge, Massachusetts 02138 / US
06 / SALMERON GARCIA, Jose Andres
c/o Werewolf Therapeutics, Inc.
1030 Massachusetts Avenue
Cambridge, Massachusetts 02138 / US
07 / BRODKIN, Heather
c/o Werewolf Therapeutics, Inc.
1030 Massachusetts Avenue
Cambridge, Massachusetts 02138 / US
08 / LIN, Shuoyen Jack
2350 Evergreen Drive
San Bruno, CA 94066 / US
09 / WESCHE, Holger
1080 Jamestown Avenue
San Francisco, CA 94124 / US
10 / SEIDEL-DUGAN, Cynthia
10 Holt Street
Belmont, MA 02478-1228 / US
 [2021/12]
Representative(s)Wilding, James Roger, et al
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
[2023/19]
Former [2021/12]Cornish, Kristina Victoria Joy, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
Application number, filing date19729416.814.05.2019
[2021/12]
WO2019US32321
Priority number, dateUS201862671225P14.05.2018         Original published format: US 201862671225 P
US201862756504P06.11.2018         Original published format: US 201862756504 P
US201862756507P06.11.2018         Original published format: US 201862756507 P
[2021/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019222295
Date:21.11.2019
Language:EN
[2019/47]
Type: A1 Application with search report 
No.:EP3794024
Date:24.03.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 21.11.2019 takes the place of the publication of the European patent application.
[2021/12]
Type: B1 Patent specification 
No.:EP3794024
Date:10.05.2023
Language:EN
[2023/19]
Search report(s)International search report - published on:EP21.11.2019
ClassificationIPC:C07K14/55, A61K38/00, C07K19/00
[2021/12]
CPC:
C07K14/55 (EP,KR,US); A61K38/00 (EP,KR,US); A61P35/00 (KR,US);
C07K14/7155 (EP); C07K16/244 (KR); C07K16/2809 (US);
C07K2317/90 (US); C07K2319/00 (EP); C07K2319/21 (EP,KR);
C07K2319/31 (KR,US); C07K2319/50 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/12]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:AKTIVIERBARE INTERLEUKIN-2-POLYPEPTIDE UND VERFAHREN ZU IHRER VERWENDUNG[2021/12]
English:ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF[2021/12]
French:POLYPEPTIDES D'INTERLEUKINE 2 ACTIVABLES ET PROCÉDÉS D'UTILISATION ASSOCIÉS[2021/12]
Entry into regional phase14.12.2020National basic fee paid 
14.12.2020Designation fee(s) paid 
14.12.2020Examination fee paid 
Examination procedure13.03.2020Request for preliminary examination filed
International Preliminary Examining Authority: EP
14.12.2020Examination requested  [2021/12]
14.12.2020Date on which the examining division has become responsible
09.08.2021Amendment by applicant (claims and/or description)
13.10.2021Despatch of a communication from the examining division (Time limit: M04)
23.02.2022Reply to a communication from the examining division
24.05.2022Despatch of a communication from the examining division (Time limit: M04)
30.08.2022Reply to a communication from the examining division
03.01.2023Communication of intention to grant the patent
30.03.2023Fee for grant paid
30.03.2023Fee for publishing/printing paid
30.03.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23171719.0  / EP4242238
Opposition(s)13.02.2024No opposition filed within time limit [2024/16]
Fees paidRenewal fee
11.05.2021Renewal fee patent year 03
21.03.2022Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT10.05.2023
CZ10.05.2023
EE10.05.2023
HR10.05.2023
LT10.05.2023
LV10.05.2023
MC10.05.2023
PL10.05.2023
RO10.05.2023
RS10.05.2023
SI10.05.2023
SK10.05.2023
SM10.05.2023
GR11.08.2023
IS10.09.2023
PT11.09.2023
[2024/25]
Former [2024/14]AT10.05.2023
CZ10.05.2023
EE10.05.2023
HR10.05.2023
LT10.05.2023
LV10.05.2023
MC10.05.2023
PL10.05.2023
RO10.05.2023
RS10.05.2023
SK10.05.2023
SM10.05.2023
GR11.08.2023
IS10.09.2023
PT11.09.2023
Former [2024/10]AT10.05.2023
CZ10.05.2023
EE10.05.2023
HR10.05.2023
LT10.05.2023
LV10.05.2023
PL10.05.2023
RO10.05.2023
RS10.05.2023
SK10.05.2023
SM10.05.2023
GR11.08.2023
IS10.09.2023
PT11.09.2023
Former [2024/08]AT10.05.2023
HR10.05.2023
LT10.05.2023
LV10.05.2023
PL10.05.2023
RS10.05.2023
SK10.05.2023
SM10.05.2023
GR11.08.2023
IS10.09.2023
PT11.09.2023
Former [2024/01]AT10.05.2023
HR10.05.2023
LT10.05.2023
LV10.05.2023
PL10.05.2023
RS10.05.2023
GR11.08.2023
IS10.09.2023
PT11.09.2023
Former [2023/51]AT10.05.2023
HR10.05.2023
PL10.05.2023
RS10.05.2023
GR11.08.2023
IS10.09.2023
PT11.09.2023
Former [2023/50]AT10.05.2023
PL10.05.2023
GR11.08.2023
IS10.09.2023
PT11.09.2023
Former [2023/48]AT10.05.2023
PT11.09.2023
Former [2023/46]PT11.09.2023
Cited inInternational search[I]DE19701141  (HOECHST AG [DE]);
 [T]EP1867660  (CSL BEHRING GMBH [DE]);
 [XI]WO2011123683  (UNIV ROCHESTER [US], et al);
by applicantWO2006110728
 US7569215
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.